Skip to main content

NextGen Discovery Series - October 20, 2021

The NextGen Precision Health Discovery Series provides learning opportunities for UM System faculty and staff across disciplines, the statewide community and our other partners to learn about the scope of precision health research and identify potential collaborative opportunities. The series consists of monthly lectures geared toward a broad multidisciplinary audience so all can participate and appreciate the spectrum of precision health efforts. 

Information about the upcoming talk, including continuing education, is available below.

For questions about this event or any others in the Discovery Series, please reach out to Mary Christie at

Precision Addiction Science Research at the University of Missouri

Speaker: Brett Froeliger, PhD, Professor, Director of Cognitive Neuroscience Systems (CNS) Core Facility

The UM system contains numerous federally funded addiction science faculty, outreach programs and training opportunities. MU is home to an NIH funded addiction training grant (T32), the MO-CARE Center – focusing on addiction science, and has developed the NextGen Cognitive Neuroscience Systems (CNS) core facility for conducting translational precision health research. Dr. Froeliger highlighted ongoing efforts from across the system for addressing drug addiction and shared his own translational research that is focused on identifying mechanisms of action of new treatments for substance use disorders.

About the SpeakerBrett Froeliger Headshot

Brett Froeliger, PhD is a Professor in the Departments of Psychology & Behavioral Science and Psychiatry, and Director of the Cognitive Neuroscience Core Facility at the University of Missouri. He completed his PhD at Southern Illinois University, postdoctoral fellowship in neuropsychopharmacology at Duke University Medical Center, joined the Neuroscience Faculty at the Medical University of South Carolina in 2013 and then joined the faculty at MU in 2020. His program of research has been continuously funded by NIH since 2012 and is organized around using brain imaging techniques to evaluate the potential benefit of novel pharmacotherapies, behavioral interventions, and non-invasive neural stimulation for treating drug addiction. 


Continuing Professional Education Credit


Up to 1.0 contact hour will be awarded to all participants who view the live sessions in their entirety and complete the evaluation form.

University of Missouri Sinclair School of Nursing is approved as a provider of nursing continuing professional development by the Midwest Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Midwest Multistate Division Provider Number MO1022-6


The Office of Continuing Education, School of Medicine, University of Missouri is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The Office of Continuing Education, School of Medicine, University of Missouri designates this live educational activity for a maximum of AMA PRA Category 1 Credit(s)™.  Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CONFLICT OF INTEREST: All persons with influence over the content of this program have been asked to disclose relevant financial interests in the last 12 months that might have an impact. John Spertus, MD, is a consultant for Jannsen, Bayer, Myokardia, Merck and Novartis, and receives research support from Abbott Vascular. No other speaker or planning committee member has a relevant financial interest.